Deucravacitinib Impurity6;1609393-48-7
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Product Code：D084006
English Name：Deucravacitinib Impurity 6
English Alias：6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
CAS No.：1609393-48-7
Molecular Formula：C₁₉H₁₇D₃N₈O₃
Molecular Weight：411.43
High-Purity Isotopic Standard：Confirmed by HPLC (≥99.0%), NMR (1H, 13C, DEPT), HRMS (isotope peak analysis), and elemental analysis, with ≥99% deuterium labeling (methyl-d3), providing an accurate isotopic internal standard for Deucravacitinib impurity analysis.
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, is used for treating autoimmune diseases such as psoriasis by regulating intracellular signaling pathways and inhibiting inflammatory responses. Impurity 10, a process-related impurity in its synthesis, may originate from side reactions during cyclopropane acylation, triazole ring construction, or subsequent condensation reactions. Its cyclopropane amide group, methoxy group, triazole ring, and carboxylic acid group may affect the drug's metabolic stability, lipophilicity, and binding ability to the target. Since drugs for treating autoimmune diseases are taken long-term, strict control of impurities is crucial for patient safety, making research on this impurity an important part of ensuring drug quality.
Detection Technology：UPLC-MS/MS technology, combined with a C18 column (1.7μm) and gradient elution with 0.1% formic acid - acetonitrile, achieves impurity separation within 8 minutes, with a detection limit as low as 0.003 ng/mL for high-precision trace impurity detection.
Formation Mechanism：Formed by the acylation reaction of 4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)pyridazine-3-carboxylic acid with cyclopropanecarbonyl chloride under the action of an alkaline catalyst (such as triethylamine). Optimizing the dosage of the catalyst and the reaction pH can effectively inhibit side reactions.
Safety Evaluation：In vitro cytotoxicity experiments show that the IC₅₀ of this impurity against HaCaT cells is 186.3 μM (Deucravacitinib IC₅₀ = 7.2 μM). Although the toxicity is lower than that of the main drug, its content in drugs still needs to be strictly controlled. Currently, long-term stability tests are being carried out to systematically study its degradation characteristics and potential risks under high temperature, high humidity, and light conditions.
NOTE！
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
NEW IN STOCK!
The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!
China
